<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; industry</title>
	<atom:link href="http://www.tapanray.in/tag/industry/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>In the Age of AI, Why Emotional Intelligence Is the New Competitive Edge in Indian Pharma Marketing</title>
		<link>http://www.tapanray.in/in-the-age-of-ai-why-emotional-intelligence-is-the-new-competitive-edge-in-indian-pharma-marketing/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=in-the-age-of-ai-why-emotional-intelligence-is-the-new-competitive-edge-in-indian-pharma-marketing</link>
		<comments>http://www.tapanray.in/in-the-age-of-ai-why-emotional-intelligence-is-the-new-competitive-edge-in-indian-pharma-marketing/#comments</comments>
		<pubDate>Sun, 16 Nov 2025 06:32:16 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[advantage]]></category>
		<category><![CDATA[AI]]></category>
		<category><![CDATA[Artificial]]></category>
		<category><![CDATA[competitive]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[edge]]></category>
		<category><![CDATA[emotional]]></category>
		<category><![CDATA[empathy]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[Intelligence]]></category>
		<category><![CDATA[leadership]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=11000</guid>
		<description><![CDATA[In today’s AI-driven world — where scientific excellence, product claims, and competitive pricing are no longer enough to differentiate pharmaceutical companies — Emotional Intelligence (EI) is rapidly emerging as the new strategic advantage in Indian pharma marketing. As doctors face shrinking time, patients demand &#8230; <a href="http://www.tapanray.in/in-the-age-of-ai-why-emotional-intelligence-is-the-new-competitive-edge-in-indian-pharma-marketing/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/in-the-age-of-ai-why-emotional-intelligence-is-the-new-competitive-edge-in-indian-pharma-marketing/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Beyond the Business Card: What Retirement Truly Gives Back</title>
		<link>http://www.tapanray.in/beyond-the-business-card-what-retirement-truly-gives-back/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=beyond-the-business-card-what-retirement-truly-gives-back</link>
		<comments>http://www.tapanray.in/beyond-the-business-card-what-retirement-truly-gives-back/#comments</comments>
		<pubDate>Sun, 26 Oct 2025 07:30:32 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[Card]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[p0wer]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[purpose]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[retirement]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10986</guid>
		<description><![CDATA[A thought-provoking LinkedIn post by a highly accomplished veteran of the pharmaceutical industry — long retired, but still as insightful as ever — recently caught my attention. It sparked a series of reflections on an issue that deeply resonates with &#8230; <a href="http://www.tapanray.in/beyond-the-business-card-what-retirement-truly-gives-back/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/beyond-the-business-card-what-retirement-truly-gives-back/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Navigating Potential US Tariffs: Challenges and AI-Driven Opportunities for Indian Pharma</title>
		<link>http://www.tapanray.in/navigating-potential-us-tariffs-challenges-and-ai-driven-opportunities-for-indian-pharma/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=navigating-potential-us-tariffs-challenges-and-ai-driven-opportunities-for-indian-pharma</link>
		<comments>http://www.tapanray.in/navigating-potential-us-tariffs-challenges-and-ai-driven-opportunities-for-indian-pharma/#comments</comments>
		<pubDate>Sat, 09 Aug 2025 08:09:51 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AI]]></category>
		<category><![CDATA[Artificial]]></category>
		<category><![CDATA[challenged]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[IMPACT]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[Intelligence]]></category>
		<category><![CDATA[opportunities]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[recommendations]]></category>
		<category><![CDATA[Strategic]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Tariff]]></category>
		<category><![CDATA[US]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10955</guid>
		<description><![CDATA[India’s pharmaceutical industry, reportedly supplying 47% of US generic drugs and exporting $27.9 billion in FY24, faces the threat of 10-25% US tariffs under a potential Trump policy. Major players like Sun Pharma, Dr. Reddy’s, Cipla, Lupin, and Aurobindo, reportedly &#8230; <a href="http://www.tapanray.in/navigating-potential-us-tariffs-challenges-and-ai-driven-opportunities-for-indian-pharma/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/navigating-potential-us-tariffs-challenges-and-ai-driven-opportunities-for-indian-pharma/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Unaccredited ‘Honorary Doctorates’: Seeking Prestige with Questionable Credentials&#8230;2</title>
		<link>http://www.tapanray.in/unaccredited-honorary-doctorates-seeking-prestige-with-questionable-credentials-2/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=unaccredited-honorary-doctorates-seeking-prestige-with-questionable-credentials-2</link>
		<comments>http://www.tapanray.in/unaccredited-honorary-doctorates-seeking-prestige-with-questionable-credentials-2/#comments</comments>
		<pubDate>Sun, 20 Jul 2025 07:34:33 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Credentials]]></category>
		<category><![CDATA[Doctorates]]></category>
		<category><![CDATA[Dr]]></category>
		<category><![CDATA[Honorary]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[Prestige]]></category>
		<category><![CDATA[questionable]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[title. PhD]]></category>
		<category><![CDATA[Unaccredited]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10943</guid>
		<description><![CDATA[Following the interest in my earlier article on this topic, I’d like to expand on it further. As previously noted, the title “Dr.” has become highly sought-after in India in recent years, especially among professionals aiming to boost their social &#8230; <a href="http://www.tapanray.in/unaccredited-honorary-doctorates-seeking-prestige-with-questionable-credentials-2/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/unaccredited-honorary-doctorates-seeking-prestige-with-questionable-credentials-2/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Regulatory Failures Are Still Risking Patient Lives</title>
		<link>http://www.tapanray.in/regulatory-failures-are-still-risking-patient-lives/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=regulatory-failures-are-still-risking-patient-lives</link>
		<comments>http://www.tapanray.in/regulatory-failures-are-still-risking-patient-lives/#comments</comments>
		<pubDate>Sun, 06 Oct 2024 06:37:45 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[failures]]></category>
		<category><![CDATA[Fake]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[Leverage]]></category>
		<category><![CDATA[lives]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[risking]]></category>
		<category><![CDATA[self-regulation]]></category>
		<category><![CDATA[standards]]></category>
		<category><![CDATA[substandard]]></category>
		<category><![CDATA[sustainabilitycompanies]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[TechnologyAwareness]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10880</guid>
		<description><![CDATA[India&#8217;s pharmaceutical industry faces renewed scrutiny as the Drug Controller General of India (DCGI) flagged numerous substandard drugs in September 2024. At the same time, an October 02, 2024, Business Standard report highlights an ongoing crackdown on such drugs by regulators. This article explores &#8230; <a href="http://www.tapanray.in/regulatory-failures-are-still-risking-patient-lives/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/regulatory-failures-are-still-risking-patient-lives/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The Indian Drug Industry’s Looming Talent Crisis &#8211; A Recent Landscape</title>
		<link>http://www.tapanray.in/the-indian-drug-industrys-looming-talent-crisis-a-recent-landscape/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-indian-drug-industrys-looming-talent-crisis-a-recent-landscape</link>
		<comments>http://www.tapanray.in/the-indian-drug-industrys-looming-talent-crisis-a-recent-landscape/#comments</comments>
		<pubDate>Thu, 18 Jul 2024 07:41:08 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[academia]]></category>
		<category><![CDATA[Academic]]></category>
		<category><![CDATA[challenge]]></category>
		<category><![CDATA[collaboration]]></category>
		<category><![CDATA[competition]]></category>
		<category><![CDATA[crisis]]></category>
		<category><![CDATA[Diversity]]></category>
		<category><![CDATA[great]]></category>
		<category><![CDATA[IMPACT]]></category>
		<category><![CDATA[inclusion]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[looming]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[re-skilling]]></category>
		<category><![CDATA[resignation]]></category>
		<category><![CDATA[shortage]]></category>
		<category><![CDATA[skill]]></category>
		<category><![CDATA[talent]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[up-skilling]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10869</guid>
		<description><![CDATA[India&#8217;s pharmaceutical industry, a global generics and drug manufacturing powerhouse, is facing a critical talent deficit. The shortage of skilled professionals is impeding innovation, drug development, and the industry&#8217;s overall competitiveness. This challenge, exacerbated by recent industry dynamics, demands immediate &#8230; <a href="http://www.tapanray.in/the-indian-drug-industrys-looming-talent-crisis-a-recent-landscape/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-indian-drug-industrys-looming-talent-crisis-a-recent-landscape/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The AI imperative: Propels Purpose-driven Leaders Revolutionizing Patient Care</title>
		<link>http://www.tapanray.in/the-ai-imperative-propels-purpose-driven-leaders-revolutionizing-patient-care/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-ai-imperative-propels-purpose-driven-leaders-revolutionizing-patient-care</link>
		<comments>http://www.tapanray.in/the-ai-imperative-propels-purpose-driven-leaders-revolutionizing-patient-care/#comments</comments>
		<pubDate>Fri, 17 May 2024 07:55:57 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AI]]></category>
		<category><![CDATA[Artificial]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[driven]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[imperative]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[Intelligence]]></category>
		<category><![CDATA[leadership]]></category>
		<category><![CDATA[PDL]]></category>
		<category><![CDATA[purpose]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10864</guid>
		<description><![CDATA[The winds of change are blowing in healthcare! Artificial Intelligence (AI) is poised to revolutionize how we deliver quality care to everyone. As a recent ET Healthworld article (March 3, 2024) aptly stated: &#8220;AI and technology are going to be transformative. The only way we can provide &#8230; <a href="http://www.tapanray.in/the-ai-imperative-propels-purpose-driven-leaders-revolutionizing-patient-care/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-ai-imperative-propels-purpose-driven-leaders-revolutionizing-patient-care/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Harness Patients’ Quest For Trusted Information From Cyberspace</title>
		<link>http://www.tapanray.in/leverage-patients-quest-for-trusted-information-from-cyberspace/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=leverage-patients-quest-for-trusted-information-from-cyberspace</link>
		<comments>http://www.tapanray.in/leverage-patients-quest-for-trusted-information-from-cyberspace/#comments</comments>
		<pubDate>Thu, 02 Nov 2023 06:40:25 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[cons]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[global India]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[Information]]></category>
		<category><![CDATA[Leverage]]></category>
		<category><![CDATA[online]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[pros]]></category>
		<category><![CDATA[quests]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10834</guid>
		<description><![CDATA[The controversy surrounding patients’ looking for health information online is virtually an ongoing one, for various reasons. Interestingly, it has been continuing at an accelerating pace for a long time. For example: “Eight in ten internet users have looked for health &#8230; <a href="http://www.tapanray.in/leverage-patients-quest-for-trusted-information-from-cyberspace/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/leverage-patients-quest-for-trusted-information-from-cyberspace/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Criticality of Bridging the Skill Gap in Today’s Indian Pharma Industry</title>
		<link>http://www.tapanray.in/criticality-of-bridging-the-skill-gap-in-todays-indian-pharma-industry/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=criticality-of-bridging-the-skill-gap-in-todays-indian-pharma-industry</link>
		<comments>http://www.tapanray.in/criticality-of-bridging-the-skill-gap-in-todays-indian-pharma-industry/#comments</comments>
		<pubDate>Sun, 17 Sep 2023 07:14:41 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[gap]]></category>
		<category><![CDATA[increase]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[PMKVY.40.]]></category>
		<category><![CDATA[productivity]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[scheme]]></category>
		<category><![CDATA[shortage]]></category>
		<category><![CDATA[skill]]></category>
		<category><![CDATA[skilled]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[training]]></category>
		<category><![CDATA[workers]]></category>
		<category><![CDATA[workforce]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10820</guid>
		<description><![CDATA[To address the shortage of adequately skilled workers in the country, in 2023, the Government of India released a new version of the national skill development initiative called Pradhan Mantri Kaushal Vikas Yojana 4.0 (PMKVY 4.0). It is touted as a &#8230; <a href="http://www.tapanray.in/criticality-of-bridging-the-skill-gap-in-todays-indian-pharma-industry/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/criticality-of-bridging-the-skill-gap-in-todays-indian-pharma-industry/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Drug Prescription In Generic Names Only, No Branded Generics</title>
		<link>http://www.tapanray.in/drug-prescription-in-generic-names-only-no-branded-generics/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=drug-prescription-in-generic-names-only-no-branded-generics</link>
		<comments>http://www.tapanray.in/drug-prescription-in-generic-names-only-no-branded-generics/#comments</comments>
		<pubDate>Sun, 20 Aug 2023 07:24:49 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[accountability.]]></category>
		<category><![CDATA[awareness]]></category>
		<category><![CDATA[branded generics]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[competition]]></category>
		<category><![CDATA[concern]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[demand]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[Draft]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[IMA]]></category>
		<category><![CDATA[increased]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[influence]]></category>
		<category><![CDATA[lack]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[names]]></category>
		<category><![CDATA[notification]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[prescription]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[rationale]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulation]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[transparency]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10812</guid>
		<description><![CDATA[The World Bank Report released on April 07, 2023 highlights that patients&#8217; Out-of-Pocket (OoP) expenses as a percentage of their total healthcare expenditure in India still accounted for as high as 50.59%. This means that patients in India generally pay for the &#8230; <a href="http://www.tapanray.in/drug-prescription-in-generic-names-only-no-branded-generics/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/drug-prescription-in-generic-names-only-no-branded-generics/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
